Guggenheim Reaffirms “Buy” Rating for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY)‘s stock had its “buy” rating reissued by equities researchers at Guggenheim in a research report issued on Tuesday,Benzinga reports. They presently have a $1,183.00 target price on the stock. Guggenheim’s price target suggests a potential upside of 20.80% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Royal Bank Of Canada began coverage on Eli Lilly and Company in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target for the company. Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday. TD Cowen boosted their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,217.59.

Eli Lilly and Company Stock Up 1.2%

Shares of NYSE:LLY traded up $11.40 on Tuesday, reaching $979.33. The company had a trading volume of 441,639 shares, compared to its average volume of 3,166,119. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a 50-day moving average price of $947.05 and a 200 day moving average price of $987.36. The stock has a market capitalization of $925.29 billion, a P/E ratio of 34.72, a P/E/G ratio of 1.13 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the previous year, the firm earned $3.34 earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 33.79 EPS for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $12,976,634,000. Capital Research Global Investors raised its holdings in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP raised its holdings in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after acquiring an additional 4,038,502 shares in the last quarter. Cardano Risk Management B.V. raised its holdings in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after acquiring an additional 2,131,734 shares in the last quarter. Finally, Fifth Third Bancorp raised its holdings in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after acquiring an additional 1,497,423 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Long?term Omvoh (mirikizumab?mrkz) data show durable disease clearance in ulcerative colitis through four years — this strengthens Lilly’s immunology franchise and supports longer product lifetime value. Lilly Omvoh 4?Year Data
• Positive Sentiment: Quarterly results: Q1 revenue jumped ~56% to $19.8B driven by Mounjaro/Foundayo demand and management raised guidance — this is the primary bullish catalyst underpinning higher earnings estimates and investor interest. Q1 Results & GLP?1 Momentum
• Positive Sentiment: Wall Street is pushing targets higher: Barclays raised its LLY target to $1,400 and Wolfe Research reiterated an outperform with a $1,325 target — analyst upgrades amplify buy interest and justify multiple expansion. Barclays Raises Target
• Positive Sentiment: Market share gains: reports show Lilly capturing roughly 60% of the GLP?1 market and Mounjaro revenue surging — supports sustained top?line growth and investor conviction in durable market leadership. GLP?1 Market Share Report
• Neutral Sentiment: Competitive backdrop: Novo Nordisk’s oral semaglutide (Wegovy pill) momentum and earlier launch timing are prompting investor debate; some stories note Novo may face pricing pressure (mixed implications for Lilly’s pricing power and market share). Novo Nordisk Pricing/Competition
• Negative Sentiment: Safety reports: the FDA has logged serious liver events tied to Foundayo and media coverage of a liver?failure case triggered a noticeable share pullback — safety headlines increase regulatory and reputational risk and are driving short?term selling pressure. FDA Foundayo Liver Report

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.